Na Xu

机构：Anhui Agricultural University, Shenzhen University, University Town of Shenzhen, Nanfang Hospital, Shenzhen University Health Science Center, Shenzhen Children's Hospital, Southern Medical University, University of International Relations

发表论文 22 篇 · 总被引 88 次 · h-index 5

代表论文

• A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera (2023 · Experimental Hematology and Oncology · 被引 34)
• Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b (2024 · British Journal of Haematology · 被引 17)
• Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study (2025 · The Lancet Haematology · 被引 9)
• Gegen Qinlian Decoction inhibits liver ferroptosis in type 2 diabetes mellitus models by targeting Nrf2 (2024 · Journal of Ethnopharmacology · 被引 9)
• Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study (2024 · Blood Cancer Journal · 被引 5)
• Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera (2025 · Blood Advances · 被引 3)